AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02620371 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: modified pectoral block
Description: Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line.
Study NCT02620371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified pectoral block
Description: Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line.
Study NCT05034666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Before the education program
Description: Before applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
Study NCT05034666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After the education program
Description: After applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
Study NCT01729247 — intervention group
Intervention type: DEVICE
Intervention: NIOX MINO® Instrument (09-1100)
Study NCT03380936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Extended Release Oral Tablet [Envarsus]
Description: Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
Study NCT03380936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange and IVIG (Intravenous Immunoglobulin )
Description: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
Study NCT03858439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Low sodium, low protein dietary recommendation
Study NCT02398227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE
Description: Cognitive Behavioral Treatment for PTSD in Battered Women
Study NCT02398227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCT
Description: Present Centered Therapy for PTSD
Study NCT02889276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Resistance Training
Description: Supervised group-based Functional Resistance Training
Study NCT02889276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised activity
Description: General activity to meet 150 minutes of moderate intensity activity per week
Study NCT00618839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft Skin Tissue
Description: StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
Study NCT00618839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cadaver allograft
Description: The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
Study NCT00712556 — intervention group
Intervention type: RADIATION
Intervention: fluorine 18-fludeoxyglucose positron emission tomography
Description: fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
Study NCT02456103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
Study NCT02721186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDA with DHAp and SLD Primaquine
Study NCT02792621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
Study NCT02792621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
Study NCT03148119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRH-882260 Heptapeptide
Description: topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a 5 amino acid linker \[Gly-Gly-Gly-Ser-Lys\] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
Study NCT03148119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scanning Fiber Endoscope
Description: Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
Study NCT01504061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mederma N&I
Description: Topical gel applied three times a day for eight weeks.
Study NCT01504061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mederma Ultra Gel
Description: Topical gel applied once daily for eight weeks.
Study NCT01714388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1mcg/kg iv dose, followed by 5 minutes ECG recording
Study NCT03094221 — intervention group
Intervention type: DEVICE
Intervention: Rhythmia Mapping System
Description: Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
Study NCT01760980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product (A) Aromasin (Exemestane)
Description: Aromasin tablets will be administered under fasting conditions on two occasions
Study NCT01760980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product (B) Exemestane
Description: Exemestane tablets will be administered under fasting conditions on one occasion
Study NCT02080000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimisation of V-V timing using R wave on surface ECG
Study NCT02080000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard V-V timing settings
Study NCT02472951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate meals
Description: Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%
Study NCT02472951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard carbohydrate meals
Description: Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%
Study NCT04712227 — intervention group
Intervention type: OTHER
Intervention: intubation
Description: intubation
Study NCT01597193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
Study NCT01597193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg/day
Study NCT01597193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: The exemestane dose is 25mg daily.
Study NCT01597193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 500 mg every 28 days
Study NCT01597193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 160 mg (4 capsules) taken orally daily.
Study NCT01597193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: The exemestane dose is 50 mg daily.
Study NCT03472287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein 1% Ointment
Description: Diacerein 1% Ointment administered topically
Study NCT01339611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
Study NCT01339611 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational program
Description: Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
Study NCT06385496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06385496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06385496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04712227 — intervention group
Intervention type: OTHER
Intervention: mask ventilation
Description: mask ventilation
Study NCT01683994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
Study NCT01683994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
Study NCT01683994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
Study NCT01683994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
Study NCT01683994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
Study NCT01683994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
Study NCT01500226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Description: (4 X 50 mg capsule) 200 mg PO
Study NCT01500226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron
Description: 2 mg PO
Study NCT01500226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 2 mg PO
Study NCT01500226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg PO
Study NCT01500226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg PO
Study NCT01500226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (4 X 0 mg capsules) 0 mg PO
Study NCT06385496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06385496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT06249542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Delivery Improvement Intervention
Description: KPWA clinical leaders and clinicians in each clinic implemented all aspects of the care delivery improvement intervention, including screening, assessment, and shared decision-making followed, as appropriate, by treatment. The implementation strategy, which was refined during the pilot phase, included:~1. Identification of a clinical champion and local implementation team~2. Participatory design~3. Training of primary care providers and medical assistants~4. Use of EHR clinical decision support tools~5. Weekly facilitated local implementation team meetings~6. Performance monitoring with feedback, including monthly meetings with the local implementation team and clinic leaders~7. Learning sessions for primary care providers during implementation~8. Social worker use of an EHR registry with weekly supervision~9. Use of a video and informational handouts to shift attitudes and reduce stigma associated with unhealthy substance use
Study NCT03989063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions to perform a motor task (external vs. internal focus instructions)
Description: During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
Study NCT03989063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructions to perform a motor task (external vs. internal focus instructions)
Description: During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
Study NCT02615756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT04404257 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ControlRad System
Description: Cardiac Catheterization or electrophysiology implant procedures with Control Rad system device installed in the cath lab room #5.
Study NCT04404257 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Without ControlRad System
Description: Cardiac Catheterization or electrophysiology implant procedures in cath lab room 5 without the ControlRad system device.
Study NCT04223154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS to the dlPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
Study NCT04223154 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS to the dlPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
Study NCT03756454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Description: Patients receiving Bezlotoxumab post-operatively.
Study NCT03756454 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo
Study NCT03557983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
Study NCT03557983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is topically spread three times per day at the irradiated areas for one week.
Study NCT02718417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given Q3W during chemotherapy phase
Study NCT02718417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given Q3W during chemotherapy phase
Study NCT01455727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
Study NCT01455727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Control patients received usual care directed by their physician.
Study NCT04170621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation using the FARAPULSE Endocardial Multi Ablation System
Study NCT03991624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cognitive assessment
Description: * MMSE : Mini-Mental State Examination~* 5 words of Dubois~* Direct Assessment of Functional Status~* Trail Making Test~* BREF : Fast Front End Efficiency Battery~* short battery of praxies~* Quality of Life in Alzheimer's Disease
Study NCT02718417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Investigator choice of weekly or Q3W during chemotherapy phase
Study NCT02718417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Investigator choice of weekly or Q3W during chemotherapy phase
Study NCT02718417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
Study NCT02718417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given as single agent in maintenance portion Q2W
Study NCT04650347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visualized internal urethrotomy
Description: incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
Study NCT04650347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: visualized internal urethrotomy
Description: incision of a urethral stricture to treat urinary obstruction using Quanta Holmium device or Sache cold knife, 18 Fr silicon catheter was kept for 7 days following the prodecure.
Study NCT00260156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT03075436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced demand-side sanitation, hygiene
Description: The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
Study NCT00260156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01577030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-fat dairy
Description: Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
Study NCT01577030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Add 4 servings fruit
Description: Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
Study NCT02341911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine,cisplatin
Description: Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
Study NCT02341911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine,carboplatin
Description: Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
Study NCT01414530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral contraceptive
Description: ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
Study NCT01414530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
Study NCT01615588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka Honey
Description: honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
Study NCT03157011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global symptom score (GSS) questionary
Description: systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.